Calliditas Therapeutics and Viatris Initiate Phase III Trial for IgA Nephropathy in Japan

05 July 2024 | Friday | News

Viatris Pharmaceutical Japan Launches VR-205 Study, Aiming to Bring Nefecon to Japanese Patients with Limited Treatment Options
Image Source : Public Domain

Image Source : Public Domain

Calliditas Therapeutics AB  announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese patients with IgA nephropathy (IgAN).

The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in design to that of the global NefIgArd trial. IgA nephropathy is a designated retractable disease in Japan, with an estimated 33,000 patients in Japan* assumed to be suffering from this disease and with limited treatment options for IgAN patients in this country.  

Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan - Calliditas Therapeutics AB


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in